Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Jasmine Zain, MD, considers how peripheral T-cell lymphoma therapy has evolved in recent years

Dr. Zain, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, considers how peripheral T-cell lymphoma (PCL) therapy has evolved in recent years

Tags: ASH Conference CoverageFeaturedLymphoma (includes NHL, HL, CNS Lymphoma)

Published: 12 December 2019

Recent Videos: Featured

video

Jasmine Zain, MD, considers how peripheral T-cell lymphoma therapy has evolved in recent years

Dr. Zain, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City ...

Related Videos

video-image

Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma

video-image

Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies

video-image

Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study

video-image

Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019

video-image

Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products

video-image

Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma

video-image

Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study

video-image

Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL

video-image

Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study

video-image

Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019

video-image

Timothy Illidge, MD, PhD, on the impact of the ECHELON-2 trial data

video-image

Ryan Lynch, MD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL

video-image

Ryan Lynch, MD, considers the ideal patient profile for zanubrutinib in RR-MCL

video-image

Christopher Yasenchak, MD, on the most impressive data in the treatment of Hodgkin’s lymphoma

video-image

Ryan Lynch, MD, tells us about the four-year update on the outcomes of the MURANO study

video-image

Chaitra Ujjani, MD, considers the ideal patient profile for zanubrutinib in RR-MCL

video-image

Angela Dispenzieri, MD, speculates on the the clinical impact of the TOURMALINE-AL1 study

video-image

Chaitra Ujjani, MD, considers how physicians should be thinking about BTK inhibitors in CLL

video-image

Angela Dispenzieri, MD, elaborates on the outcomes from the TOURMALINE-AL1 study

video-image

Chaitra Ujjani, MD, tells us about Veneto-STOP study presented at ASH 2019

video-image

Angela Dispenzieri, MD, shares the design of the TOURMALINE-AL1 study presented at ASH 2019

video-image

Jeffrey Sharman, MD, on the benefits of zanubrutinib as compared to other BTK inhibitors

video-image

Daniel Pollyea, MD, speculates on how oral HMAs will impact the landscape in myeloid malignancies

video-image

Jeffrey Sharman, MD, explains how we should be thinking about BTK inhibitors in the treatment of CLL

video-image

Daniel Pollyea, MD, provides opinion on current treatment strategies for elderly AML patients

video-image

Jeffrey Sharman, MD, shares updates from the CLL14 study presented at ASH 2019

video-image

Daniel Pollyea, MD, discusses prognostic factors in acute myeloid leukemia (AML) patients

video-image

Jeffrey Sharman, MD, tells us about the design and outcomes of the Phase 3 ELEVATE TN from ASH 2019

video-image

Daniel Pollyea, MD, discusses the most promising emerging strategies in the management of AML

video-image

Andre Goy, MD, considers whether off-the-shelf CAR-T cell therapies are becoming a reality

video-image

Daniel Pollyea, MD, elaborates on the evolving treatment landscape in myelodysplastic syndromes

video-image

Andre Goy, MD, on the TRANSCEND-CLL-004 data investigating the use of CAR-T cell therapy DLBCL

video-image

Jae H. Park, MD, on incorporating CAR-T cell therapies into acute leukemia treatment algorithms

video-image

Andre Goy, MD, discusses the three-year survival analysis of the ZUMA-1 study from ASH 2019

video-image

Jae H. Park, MD, on the factors associated with improved survival after CD19 CAR-T cell therapy

video-image

Andre Goy, MD, regarding the ZUMA-2 study investigating anti-CD19 CAR-T cell therapy MCL

video-image

Jae H. Park, MD, regarding combination vemurafenib and obinutuzumab in hairy cell leukemia patients

video-image

Constantine Tam, MBBS, MD, regarding the patient profile in MCL most suitable for zanubrutinib

video-image

Chaitra Ujjani, MD, tells us about the results of the Phase 3 ELEVATE TN study in CLL

video-image

Angela Dispenzieri, MD, expands on the side effects from the TOURMALINE-AL1 study

video-image

Amrita Krishnan, MD, elaborates on BCMA-directed strategies for multiple myeloma patients

video-image

Chaitra Ujjani, MD, offers her impression of the Phase 2 CAPTIVATE study in CLL

video-image

Amrita Krishnan, MD, tells us about the Phase 3 Dreamm-3 study presented at ASH 2019

video-image

David Andorsky, MD, defines RWE and explains how it compliments clinical trial results

video-image

Christopher Yasenchak, MD, on 1st line brentuximab vedotin + nivolumab in Hodgkin’s lymphoma

video-image

David Andorsky, MD, provides examples of how RWE has impacted the oncology community

video-image

Christopher Yasenchak, MD, tells us about the patient profile most suited for zanubrutinib in MCL

video-image

David Andorsky, MD, on the results of his RWE study investigating idelalisib in follicular lymphoma

video-image

Amrita Krishnan, MD, tells us about the outcomes of the CARTITUDE-1 study presented at ASH 2019

video-image

David Andorsky, MD, discusses the implications of real-world evidence for oncologists

video-image

Amrita Krishnan, MD, tells us about the results of the Phase 1 study investigating CC-93269 in MM

video-image

James Essell, MD, offers opinion on the future of off-the-shelf CAR-T cell therapy

video-image

Amer Zeidan, MBBS, considers RWE in older patients with acute myeloid malignancies

video-image

James Essell, MD, regarding off-the-shelf CAR NK cell therapy in treating B-cell malignancies

video-image

Amer Zeidan, MBBS, speculates on the role of immune checkpoint blockades in myeloid malignancies

video-image

James Essell, MD, offers his impression the data investigating the bi-specific CAR-T cell therapy

video-image

Amer Zeidan, MBBS, elaborates on the role of venetoclax in treatment of MDS

video-image

James Essell, MD, discusses the integration of stem cell transplantation in the treatment of myeloma

video-image

Amer Zeidan, MBBS, on the role of oral therapies in the treatment of myeloid malignancies

video-image

Constantine Tam, MBBS, MD, considers the role of CAR-T cell therapy in chronic lymphocytic leukemia

video-image

Peter M. Voorhees, MD, explains how daratumumab is changing the way MM patients are treated today

video-image

Constantine Tam, MBBS, MD, tells us about the Phase 2 CAPTIVATE study presented at ASH 2019

video-image

Peter M. Voorhees, MD, summarizes the outcomes of the Phase 2 Griffin study in newly diagnosed MM

video-image

Constantine Tam, MBBS, MD, compares the benefits of zanubrutinib to other BTK inhibitors

video-image

Shyamala Navada, MD, MSCR, discusses the treatment of elderly patients with myeloid malignancies

video-image

Constantine Tam, MBBS, MD, regarding the data that lead to the recent FDA approval of zanubrutinib

video-image

Sattva Neelapu, MD, tells us about the results of the ZUMA-1 study in DLBCL presented at ASH 2019

video-image

Shyamala Navada, MD, MSCR, offers opinion on how the treatment landscape of MDS is evolving

video-image

Sattva Neelapu, MD, considers whether off-the-shelf CAR-T cell therapy is becoming a reality

video-image

Constantine Tam, MBBS, MD, offers his impression of the Phase 2 CAPTIVATE study in CLL from ASH '19

video-image

Sattva Neelapu, MD, on the role of CAR NK cell therapy in the treatment of B-cell malignancies

video-image

Shyamala Navada, MD, MSCR, on how oral therapies will impact the treatment of myeloid malignancies

video-image

John Burke, MD, regarding tafasitamab or tafasitamab + lenalidomide in addition to R-CHOP in DLBCL

video-image

John Burke, MD, offers opinion on how physicians should be thinking about the use of BTK inhibitors

video-image

Robert Rifkin, MD, FACP, on whether medical oncologists are embracing therapeutic biosimilars

video-image

John Burke, MD, outlines the patient profile best suited for zanubrutinib in relapsed/refractory MCL

video-image

Robert Rifkin, MD, FACP, on the role of daratumumab as maintenance therapy in the management of MM

video-image

Luciano J. Costa, MD, PhD, offers opinion on whether MRD tests can help guide treatment decisions

video-image

Robert Rifkin, MD, FACP, offers opinion on the most promising studies in MM presented at ASH 2019

video-image

Luciano J. Costa, MD, PhD, explains how academic and community oncologists can utilize MRD tests

video-image

Courtney DiNardo, MD, provides opinion on current treatment strategies for elderly AML patients

video-image

Jasmine Zain, MD, shares outcomes from the PRIMO study investigating duvelisib in PTCL

video-image

Courtney DiNardo, MD, describes the targeted therapy landscape in acute myeloid leukemia

video-image

Jasmine Zain, MD, tells us about the novel approaches in development for the treatment of PTCL

video-image

Courtney DiNardo, MD, regarding the evolution of treatment in acute myeloid leukemia

video-image

Jasmine Zain, MD, discusses the most impressive studies in PTCL presented at ASH 2019

video-image

Courtney DiNardo, MD, considers the role of intensive chemotherapy in newly diagnosed AML

video-image

Max Topp, MD, on whether a risk management plan exists to help reduce toxicity of CAR-T cell therapy

video-image

Bruce Feinberg, DO, elaborates on how oncologists are utilizing real-world evidence today

video-image

John Seymour, MBBS, PHD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL

video-image

Bruce Feinberg, DO, provides examples of how RWE has impacted decision-making in oncology

video-image

John Seymour, MBBS, PHD, elaborates on the updated data from the Phase 3 MURANO trial

video-image

Bruce Feinberg, DO, defines and explains the role of real-world evidence

video-image

Kylee Martens, MD, compares rasburicase versus allopurinol in patients with hyperuricemia

video-image

Michael Wang, MD, regarding the pivotal clinical data that lead to the FDA approval of zanubrutinib

video-image

Michael Wang, MD, speculates on therapies for front-line and relapsed mantle cell lymphoma

video-image

Michael Wang, MD, on the distinct advantages of zanubrutinib in the management of lymphoma

video-image

Kylee Martens, MD, on the role of rasburicase in managing TLS in patients with renal dysfunction

video-image

Kylee Martens, MD, on those patient types more suited for treatment with rasburicase vs. allopurinol

video-image

Max Topp, MD, shares the long-term results of the ZUMA-1 trial presented at ASH 2019

video-image

Kylee Martens, MD, considers whether there are certain patient types more prone to TLS

video-image

Luciano J. Costa, MD, PhD, on whether minimal residual disease can be used to predict outcomes

video-image

Robert Rifkin, MD, FACP, tells us about the outcomes of the LYRA study presented at ASH 2019

video-image

Luciano J. Costa, MD, PhD, on how measurement of MRD is evolving as an endpoint in clinical trials

video-image

Catherine Diefenbach, MD, explains how combination therapies are evolving in follicular lymphoma

video-image

Joseph Alvarnas, MD, on seeking creative solutions to provide proper access to innovative therapy

video-image

Saro Armenian, DO, MPH, reflects on promising clinical innovations in the management of leukemia

video-image

Joseph Alvarnas, MD, on the challenges facing cancer centers when delivering innovative therapies

video-image

Saro Armenian, DO, MPH, considers the relevance of bone marrow transplant in leukemia & lymphoma

video-image

Catherine Diefenbach, MD, regarding the unmet needs in the management of follicular lymphoma

video-image

Saro Armenian, DO, MPH, on bone marrow transplant survivorship outcomes in AML patients

video-image

Michael Wang, MD, shares details from the ZUMA-2 trial in mantle cell lymphoma presented at ASH 2019

video-image

Joseph Alvarnas, MD, regarding CAR-T cell therapy in an era of value-based care

video-image

Catherine Diefenbach, MD, on the recent data investigating obinutuzumab in follicular lymphoma

video-image

Andrew Cowan, MD, elaborates on the role of isatuximab in the management of multiple myeloma

video-image

Joseph Alvarnas, MD, on how to responsibly integrate clinical innovations into treatment algorithms

video-image

Michael Jain, MD, offers his opinion on off-the-shelf CAR-T cell therapy

video-image

James McCloskey, MD, regarding the QUASAR-001 study presented at ASH 2019

video-image

Michael Jain, MD, shares the outcomes of the US CAR-T Cell Consortium study from ASH 2019

video-image

Andrew Cowan, MD, on the most promising clinical data in multiple myeloma presented at ASH 2019

video-image

James McCloskey, MD, considers how the role of molecular profiling in AML is changing

video-image

Michael Jain, MD, discusses how population-based outcomes in B-cell lymphomas are changing

video-image

Andrew Cowan, MD, provides an overview of the use of CAR-T cell therapy in multiple myeloma

video-image

James McCloskey, MD, speculates on the landscape of MDS as a result of data presented at ASH '19

video-image

Michael Jain, MD, offers perspective on the latest treatment trends for aggressive lymphomas

video-image

James McCloskey, MD, shares his impression of the Phase 3 ASCERTAIN trial in MDS

video-image

Andrew Cowan, MD, discusses the role of human BCMA CAR-T cells in the management of multiple myeloma

video-image

Michael Jain, MD, regarding CAR-natural killer (NK) cell therapy

video-image

Lori Leslie, MD, on real-world evidence regarding CAR-T cell therapy in lymphoma

video-image

Lori Leslie, MD, offers perspective on the role of umbralisib in relapsed/refractory lymphoma

video-image

John Mascarenhas, MD, on JAK inhibitors & combination therapies in myeloproliferative neoplasms

video-image

Lori Leslie, MD, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma

video-image

John Mascarenhas, MD, on the role of molecular analysis in myeloproliferative neoplasms

video-image

Lori Leslie, MD, considers how physicians should be thinking about the use of BTK inhibitors in CLL

video-image

John Mascarenhas, MD, on the individualized management of myeloproliferative neoplasms

video-image

Lori Leslie, MD, offers her perspective on the latest treatment trends in aggressive lymphomas

video-image

Joshua Richter, MD, on the Phase 3 ICARIA-MM study from the 61st ASH Annual Meeting and Exposition

video-image

John Mascarenhas, MD, shares outcomes from the MANIFEST study examining CPI-0610 in myelofibrosis

video-image

Joshua Richter, MD, discusses the data investigating iberdomide presented at ASH 2019

video-image

Joshua Richter, MD, provides opinion on the role of BCMA CAR-T cells in the management of MM

video-image

Parameswaran Hari, MD, MRCP, offers his impression of the Phase 3 ICARIA-MM trial from ASH 2019

video-image

Joshua Richter, MD, regarding the Phase 3 CANDOR study in relapsed/refractory multiple myeloma

video-image

Parameswaran Hari, MD, MRCP, on novel combination treatment options & sequencing strategies in MM

video-image

Parameswaran Hari, MD, MRCP, considers the role of stem cell transplantation in myeloma

video-image

Parameswaran Hari, MD, MRCP, tells us about the design & outcomes of the STORM and Mammoth studies

video-image

Deepu Madduri, MD, explains how JNJ-4528 differs from other CAR-T products

video-image

Leslie Popplewell, MD, summarizes the role of checkpoint inhibitors in the treatment of lymphomas

video-image

Catherine Smith, MD, discusses prognostic factors and outcomes in acute myeloid leukemia

video-image

Leslie Popplewell, MD, on the role of CAR-T cell therapy in aggressive B-cell lymphomas

video-image

Catherine Smith, MD, offers her overall impression on the changing FLT3 inhibition landscape in AML

video-image

Leslie Popplewell, MD, considers the use of CAR-T cell therapies in aggressive B-cell lymphomas

video-image

Catherine Smith, MD, on whether all acute myeloid leukemia patients should be tested for FLT3

video-image

Leslie Popplewell, MD, considers whether there is sufficient evidence supporting bridging therapy

video-image

Deepu Madduri, MD, on how CAR-T cell therapy plays a role in the management of multiple myeloma

video-image

Catherine Smith, MD, tells us about the outcomes of the Phase 3 ADMIRAL trial presented at ASH 2019

video-image

Leslie Popplewell, MD, offers opinion on the next frontier in the development of CAR-T treatment

video-image

Deepu Madduri, MD, elaborates on the outcomes of the CARTITUDE-1 study

video-image

Paul M. Barr, MD, considers the role of CAR-T therapy in B-cell lymphomas

video-image

Andre Goy, MD, explains how lenalidomide will impact the management of FL and MZL

video-image

Andre Goy, MD, discusses the role of CAR-T therapy in lymphomas

video-image

Andre Goy, MD, shares the most exciting advances in lymphoma coming out of ASCO 2019

video-image

Andrew Goy, MD, explains how the approval of lenalidomide will impact the management of FL & MZL

video-image

Andrew Goy, MD, discusses the role of CAR-T therapy in lymphomas

video-image

Andrew Goy, MD, elaborates on the most exciting recent clinical advances in lymphoma

video-image

Lori A. Leslie, MD, on the recent data regarding umbralisib in relapsed/refractory lymphoma

video-image

Lori A. Leslie, MD, speculates on how CAR-T cell therapy may be combined to treat lymphomas

video-image

Lori A. Leslie, MD, on how CAR-T cell therapy has impacted the treatment of B-cell lymphomas

video-image

Carol Moreno, MD, PhD, on the Phase 3 trial examining ibrutinib + rituximab versus FCR in CLL

video-image

Carol Moreno, MD, PhD, on how the outcomes of the illUMINTATE trial impact treatment of CLL

video-image

Jasmine Zain, MD, on the most exciting studies in lymphoma presented at ASH 2018

video-image

Yana Pikman, MD, regarding research outcomes from the LEAP Consortium

video-image

Jasmine Zain, MD, discusses novel treatment research regarding transplants at City of Hope

video-image

Jasmine Zain, MD, considers the impact of the new induction regimen in PTCL

video-image

Yana Pikman, MD, on the efforts of the LEAP Consortium in pediatric acute leukemia

video-image

Jasmine Zain, MD, defines successful induction regimens when treating PTCL

video-image

Jasmine Zain, MD, elaborates on the investigation of novel induction regimens in PTCL

video-image

Jasmine Zain, MD, regarding the standard of care in treatment of PTCL

video-image

Rod A. Humerickhouse, MD, PhD, describes recent advancements in the treatment of CLL

video-image

Rod A. Humerickhouse, MD, PhD, considers testing for minimal residual disease in CLL

video-image

Rod A. Humerickhouse, MD, PhD, on MRD as a surrogate marker in chronic lymphocytic leukemia

video-image

Jason Butler, PhD, considers how vascular integrity impacts the leukemia-initiating metabolic switch

video-image

Rena Feinman, PhD, considers the the role of the microbiome in cancer & response to therapy

video-image

Jason Butler, PhD, on how age-associated aberrant MAPK signaling impacts hematopoiesis

video-image

Rod A. Humerickhouse, MD, PhD, regarding potential side effects from venetoclax + rituximab in CLL

video-image

Sen Zhuang, MD, PhD, shares the research & development philosophy at Janssen

video-image

Rod A. Humerickhouse, MD, PhD, on treating CLL patients with venetoclax and rituximab

video-image

Sen Zhuang, MD, PhD, shares details from the LCAR-838M study in relapsed/refractory MM

video-image

Sen Zhuang, MD, PhD, speculates on how LCAR-838M may impact the treatment of MM

video-image

Sen Zhuang, MD, PhD, regarding the development of LCAR-B38M

video-image

Rod A. Humerickhouse, MD, PhD, elaborates on venetoclax in treatment of MM

video-image

Katja Weisel, MD, provides opinion on anti-BCMA CAR-T cell therapy in multiple myeloma

video-image

Habte Yimer, MD, considers the outcomes of the GRIFFIN study in multiple myeloma

video-image

Katja Weisel, MD, discusses current maintenance regimens in multiple myeloma

video-image

Habte Yimer, MD, speculates on the future of anti-BCMA CAR-T cell therapy

video-image

Keith Pratz, MD, considers emerging therapies for newly diagnosed or relapsed AML patients

video-image

Katja Weisel, MD, elaborates on the outcomes of the TOURMALINE-MM3 study

video-image

Habte Yimer, MD, regarding the POLLUX and CASTOR studies presented at ASH 2018

video-image

Sattva Neelapu, MD, speculates on the future of CAR-T therapies in lymphoma

video-image

Keith Pratz, MD, on genetic testing in AML prior to the start of therapy

video-image

Katja Weisel, MD, shares outcomes of the POLLUX and CASTOR studies from ASH 2018

video-image

Habte Yimer, MD, regarding the Lyra trial in newly diagnosed multiple myeloma presented at ASH 2018

video-image

Peter Vorhees, MD, describes what regimens are being used for multiple myeloma patients today

video-image

Peter Vorhees, MD, discusses the outcomes of the TOURMALINE-MM3 study in MM

video-image

Peter Vorhees, MD, discusses outcomes of the ALCYONE trial in multiple myeloma patients

video-image

Carol Moreno, MD, PhD, discusses MRD as a legitimate surrogate marker in CLL

video-image

Carol Moreno, MD, PhD, describes recent advancements in the treatment of CLL

video-image

Keith Pratz, MD, comments on the Phase I study of gilteritinib presented at ASH 2018

video-image

Carol Moreno, MD, PhD, shares outcomes from the iLLUMINATE trial presented at ASH 2018

video-image

Sattva Neelapu, MD, considers the use of axicabtagene ciloleucel with elderly lymphoma patients

video-image

Keith Pratz, MD, regarding the reliability of the companion diagnostic test for FLT3

video-image

Sattva Neelapu, MD, on real-world experience & clinical studies examining axicabtagene ciloleucel

video-image

Keith Pratz, MD, describes how gilteritinib fits into treatment algorithms for AML

video-image

Sattva Neelapu, MD, regarding the ZUMA-1 two-year follow-up study in DLBCL

video-image

James McCloskey, MD, elaborates on the role of molecular testing in newly diagnosed AML

video-image

Rafael Fonseca, MD, on the effectiveness of anti-BCMA CAR-T cell therapy in multiple myeloma

video-image

James McCloskey, MD, regarding molecular testing in acute myelogenous leukemia

video-image

Rafael Fonseca, MD, discusses maintenance regimens for multiple myeloma

video-image

James McCloskey, MD, considers the application of the FLT3 test in newly diagnosed AML patients

video-image

Rafael Fonseca, MD, regarding the TOURMALINE-MM3 study in multiple myeloma

video-image

James McCloskey, MD, describes how the FLT3 mutation influences treatment decisions in AML

video-image

Rafael Fonseca, MD, elaborates on the outcomes of the POLLUX and CASTOR studies in MM

video-image

James McCloskey, MD, speculates on the reliability of the companion diagnostic test for FLT3

video-image

Rafael Fonseca, MD, discusses frontline multiple myeloma treatment patterns

video-image

Edward Copelan, MD, considers the role of allogeneic transplantation in lymphoma & multiple myeloma

video-image

Edward Copelan, MD, regarding gilteritinib for patients with FLT3+ AML

video-image

Nikhil Munshi, MD, discusses the outcomes of the TOURMALINE-MM3 study in multiple myeloma

video-image

Nikhil Munshi, MD, discusses the POLLUX and CASTOR studies regarding the use of daratumumab in MM

video-image

Nikhil Munshi, MD, regarding the outcomes of the CA204-142 study from ASH 2018

video-image

Nikhil Munshi, MD, considers how ID2 function impacts oncogenesis in multiple myeloma

video-image

Andrew Pecora, MD, shares his thoughts on the necessity of allogeneic transplants to MML patients

video-image

Nizar Bahlis, MD, speculates on the future of anti-BCMA CAR-T cell therapy in MM

video-image

Nizar Bahlis, MD, describes current maintenance regimens for multiple myeloma

video-image

John Burke, MD, elaborates on the Beat AML umbrella study

video-image

Nizar Bahlis, MD, discusses the outcomes of the TOURMALINE-MM3 study from ASH 2018

video-image

John Burke, MD, comments on clinical research examining gilteritinib in newly diagnosed AML

video-image

Nizar Bahlis, MD, regarding the impact of the POLLUX and CASTOR studies from ASH 2018

video-image

John Burke, MD, elaborates on the incorporation of venetoclax into AML treatment regimens

video-image

Elizabeth Budde, MD, evaluates the clinical study investigating mosunetuzumab from ASH 2018

video-image

John Burke, MD, speaks to the reliability of the FLT3 mutation test

video-image

Elizabeth Budde, MD, on how City of Hope has overcome logistical hurdles associated with CAR-T

video-image

John Burke, MD, regarding gilteritinib in acute myeloid leukemia treatment

video-image

Elizabeth Budde, MD, discusses the role of CAR-T therapies in lymphoma treatment algorithms

video-image

Robert Rifkin, MD, shares his thoughts on if a rituximab biosimilar can replace rituximab

video-image

Robert Rifkin, MD, discusses the rationale for genetically profiling AML patients

video-image

Robert Rifkin, MD, explains whether or not anti-BCMA CAR-T cell therapy looks promising

video-image

Robert Rifkin, MD, discusses the outcomes of the TOURMALINE-MM3 study

video-image

Robert Rifkin, MD, talks about what clinical data could change the way multiple myeloma is treated

video-image

Ravi Vij, MD, on molecular testing and acute myelogenous leukemia

video-image

Samer Khaled, MD, tells us about the MEDALIST study examining myelodysplastic syndrome

video-image

Ravi Vij, MD, considers anti-BCMA CAR-T cell therapy in multiple myeloma

video-image

Ravi Vij, MD, discusses current maintenance regimens for multiple myeloma

video-image

Samer Khaled, MD, on incorporating venetoclax into treatment regimens for AML

video-image

Ravi Vij, MD, shares details regarding his clinical study presented at ASH 2018

video-image

Samer Khaled, MD, regarding gilteritinib in treatment of acute myelogenous leukemia

video-image

Samer Khaled, MD, shares details of his study examining the use of CAR-T therapy in ALL

video-image

Ravi Vij, MD, regarding the POLLUX and CASTOR clinical studies in multiple myeloma

video-image

Andrzej Jakubowiak, MD, shares thoughts on the POLLUX and CASTOR clinical studies

video-image

Andrzej Jakubowiak, MD, PhD, discusses maintenance regimens in treatment of multiple myeloma

video-image

Andrzej Jakubowiak, MD, PhD, regarding the ALCYONE trial presented at ASH 2018

video-image

Andrzej Jakubowiak, MD, discusses the outcomes of the GRIFFIN study from ASH 2018

video-image

Chadi Nabhan, MD, MBA, on the role of advanced practice practitioners

video-image

Chadi Nabhan, MD, MBA, shares what is being done to prevent oncologist burnout

video-image

Chadi Nabhan, MD, MBA, discusses the key factors contributing to physician burnout

video-image

Chadi Nabhan, MD, MBA, regarding the risks related to two-sided payment agreements

video-image

Chadi Nabhan, MD, MBA, elaborates on the skepticism regarding MACRA

video-image

Sundar Jagannath, MD, discusses the role of checkpoint inhibitors in treatment of MM

video-image

Sundar Jagannath, MD, regarding proteasome inhibitors in the treatment of MM

video-image

Maria-Victoria Mateos, MD, elaborates on the TOURMALINE-MM3 presented at ASH 2018

video-image

Maria-Victoria Mateos, MD, on the addition of daratumumab to revlimid/dexamethasone in MM

video-image

Sundar Jagannath, MD, considers maintenance regimens for multiple myeloma (MM) patients

video-image

Sundar Jagannath, MD, elaborates on the outcomes of CA204-142 in MM

video-image

Maria-Victoria Mateos, MD, regarding the CASTOR trial presented at ASH 2018

video-image

Maria-Victoria Mateos, MD, shares outcomes from the ALCYONE study in MM

video-image

Jeff Sharman, MD, shares his thoughts on rituximab biosimilars in follicular lymphoma

video-image

Lorenz Trumper, MD, discusses the results of ECHELON-2 in frontline PTCL

video-image

Jeff Sharman, MD, on the outcomes of CAPTIVATE study investigating ibrutinib and venetoclax

video-image

Jeff Sharman, MD, on how important the CLL-14 study is in determining CLL treatment strategies

video-image

Lorenz Trumper, MD, on the current standard of care for the frontline treatment of PTCL

video-image

Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in younger CLL patients

video-image

Lorenz Trumper, MD, speaks on the differences between B-Cell and T-Cell lymphomas

video-image

Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in older CLL patients

video-image

Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL

video-image

Swaminathan P. Iyer, MD, shares exciting studies regarding the treatment of PTCL from ASH 2018

video-image

Swaminathan P. Iyer, MD, on the outcomes of the ECHELON-2 study in PTCL

video-image

Andre Goy, MD, comments on the long-term outcome of acalabrutinib in MCL

video-image

Andre Goy, MD, on immunotherapy and the treatment of hematologic malignancies

video-image

Andre Goy, MD, considers checkpoint inhibitors in hematologic malignancies

video-image

Andre Goy, MD, discusses his real-world experience using axi-cel CAR-T cell therapy

video-image

Andre Goy, MD, on research regarding the use of axi-cel CAR-T cell therapy in DLBCL

video-image

Tatyana Feldman, MD, regarding improvements in the treatment of CTCL

video-image

Tatyana Feldman, MD, on exciting studies from ASH 2018 regarding the treatment of PTCL

video-image

Frederick Locke, MD, on whether CAR-T therapies will be expanded into solid tumors

video-image

Frederick Locke, MD, on the management of toxicity withs with CAR-T therapies

video-image

Julie Vose, MD, on management of common toxicities with CAR-T therapies

video-image

David Siegel, MD, explains the results of MM014 study presented at ASH

video-image

Julie Vose, MD, discusses improvements made in the delivery of CAR-T therapies in lymphoma

video-image

Frederick Locke, MD, on what improvements to turn around time with CAR-T therapies

video-image

David Siegel, MD, discusses anti-BCMA CAR-T cell therapy for multiple myeloma patients

video-image

Frederick Locke, MD, discusses how to integrate CAR-T with stem cell transplant

video-image

Andre Goy, MD, on responses & outcomes when treating lymphoma with CAR-T therapies

video-image

Tatyana Feldman, MD, shares outcomes of the ECHELON-2 study in PTCL

video-image

David Siegel, MD, talks about the TOURMALINE-MM3 study and the treatment of multiple myeloma

video-image

Tatyana Feldman, MD, offers opinion on the ECHELON-2 study in PTCL

video-image

Frederick Locke, MD, on the use of CAR-T therapies in leukemia and lymphoma

video-image

Tatyana Feldman, MD, on unmet needs in peripheral T-cell lymphoma (PTCL)

video-image

Julie Vose, MD, on if CAR-T therapies are showing impressive results in lymphoma

video-image

Andrew Pecora, MD, tells us about the results of the CPIT trial presented here at ASH

video-image

David Siegel, MD, shares his thoughts on the daratumamab studies presented at ASH 2018

video-image

Julie Vose, MD, tells us about the results of the AUGMENT study in relapsed/refractory indolent NHL

video-image

Julie Vose, MD, discusses whether polatuzumab improves outcomes in DLBCL patients

video-image

Andre Goy, MD, discusses how CAR-T therapies are being integrated into the treatment of large B-Cell lymphoma

video-image

Ravi Vij, MD, on the outcomes of the TOURMALINE-MM3 study in multiple myeloma

video-image

Swaminathan Padmanabhan Iyer, MD, on if ECHELON-2 study is game changing for patients with PTCL

video-image

Keith Pratz, MD, discusses venetoclax in treatment of acute myeloid leukemia (AML)

video-image

James McClosky, MD, on using newly FDA approved gilteritinib for patients with AML

video-image

Peter Vorhees, MD, discusses the outcomes of the GRIFFIN trial in multiple myeloma

video-image

Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285

video-image

Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis

video-image

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of BLU-285 and what makes it unique

video-image

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

video-image

Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD

video-image

Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients

video-image

Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated

video-image

Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint

video-image

Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients

video-image

Jesus San-Miguel, MD, on the role of daratumumab in the front-line setting in multiple myeloma (MM)

video-image

Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment

video-image

Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL

video-image

James R. Downing, MD, explains the mission of St. Jude Children’s Research Hospital

video-image

Andrew Lane, MD, PhD, on how frequently clinicians interact with frail AML patients

video-image

Andrew Lane, MD, PhD, on treatment approaches when managing frail AML patients

video-image

Andrew Lane, MD, PhD, offers strategies for clinicians when treating frail AML patient populations

video-image

Andrew Lane, MD, PhD, shares outcomes from the phase 2 study of SL-401 in patients with BPDCN

video-image

Jesus San-Miguel, MD, on daratumumab in a first-line setting as a result of the ALCYON study

video-image

Jesus San-Miguel, MD, explains the efficacy and safety outcomes of the ALCYON clinical study

video-image

Jens G. Lohr, MD, PhD, discusses the kind of information we can gather from liquid biopsy

video-image

Jens G. Lohr, MD, PhD, on utilizing liquid biopsy and how it compares to bone marrow biopsy

video-image

James Essell, MD, discusses the concerns for patients receiving allogeneic transplantations

video-image

James Essell, MD, on how allogeneic transplantation is incorporated into hematologic malignancy

video-image

Brad S. Kahl, MD, considers the unmet medical needs in treatment of Hodgkin lymphoma

video-image

Brad S. Kahl, MD, discusses the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma

video-image

Brad S. Kahl, MD, tells us about his study evaluating ADCT-402 in DLBCL

video-image

Jorge Cortes, MD, on how generic imatinib is being adopted as an alternative to branded imatinib

video-image

Jorge Cortes, MD, on what was discussed at ASH 2017 regarding treatment discontinuation in AML

video-image

Simon Rule, MD, considers the clinical development plan with Imbruvica in mantle cell lymphoma (MCL)

video-image

Simon Rule, MD, discusses the ibrutinib data in relapsed/refractory MCL presented at ASH 2017

video-image

Edward A. Copelan, MD, shares highlights from ASH 2017 regarding treatment of acute myeloid leukemia

video-image

Edward A. Copelan, MD, on allogeneic transplantation & CAR T-cell therapy in lymphoma and myeloma

video-image

Edward A. Copelan, MD, considers whether azacitidine can be used for induction in AML

video-image

James R. Downing, MD, discusses the significant studies presented at ASH 2017

video-image

James R. Downing, MD, on the evolution of St. Jude Children’s Research Hospital

video-image

John Burke, MD, on rituximab as an effective strategy after 1st line bendamustine-rituximab in FL

video-image

Keith Pratz, MD, on the proportion of AML patients who fall into the frail category

video-image

Keith Pratz, MD, explains how he is incorporating Vyxeos into his treatment of AML patients

video-image

Keith Pratz, MD, suggests strategies for clinicians when treating frail AML patients

video-image

Keith Pratz, MD, on exciting clinical data regarding FTL3 tyrosine kinase inhibitors in AML patients

video-image

Keith Pratz, MD, shares the outcome of the venetoclax study in treatment-naive AML patients

video-image

Keith Pratz, MD, on combining ivosidenib or enasidenib with chemotherapy in AML

video-image

Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML

video-image

Fredrick B. Hagemeister, MD, on the exploration of CAR T-cell therapies in various lymphoma types

video-image

Fredrick B. Hagemeister, MD, describes how PD-1 inhibitors are being incorporated into FL treatment

video-image

Fredrick B. Hagemeister, MD, on managing toxicities associated with CAR T-cell therapies

video-image

Fredrick B. Hagemeister, MD, on what we should know about CAR T-cell therapies

video-image

Andrew Lane, MD, PhD, on minimal residual disease and AML treatment decisions

video-image

John Burke, MD, lists the top findings from ASH 2017 regarding lymphoid malignancies

video-image

John Burke, MD, on combination atezolizumab, obinutuzumab, and bendamustine in follicular lymphoma

video-image

Habte Yimer, MD, on daratumumab, cyclophosphamide, bortezomib, & dexamethasone in relapsed MM

video-image

Habte Yimer, MD, considers the impact of combination obinutuzumab and bendamustine on CLL patients

video-image

Martin Hutchings, MD, details the role of PET in the management of Hodgkin’s lymphoma

video-image

Martin Hutchings, MD, considers how the ECHELON-1 study could be practice changing

video-image

Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017

video-image

Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients

video-image

Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment

video-image

Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy

video-image

Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML

video-image

Michael Boxer, MD, on the effectiveness of fostamatinib in the maintenance of ITP responses

video-image

Parameswaran Hari, MD, MRCP, MS, considers the remaining unmet medical needs in MM

video-image

Parameswaran Hari, MD, MRCP, MS, discusses the clinical relevance of minimal residual disease

video-image

Parameswaran Hari, MD, MRCP, MS, provides an update on how MM patients are staged at diagnosis

video-image

Parameswaran Hari, MD, MRCP, MS, on promising cellular immunotherapy studies from ASH 2017

video-image

Parameswaran Hari, MD, MRCP, MS, on how the field of immunotherapy is evolving for MM patients

video-image

Parameswaran Hari, MD, MRCP, MS, on checkpoint inhibitors and MM treatment algorithms

video-image

David Miklos, MD, PhD, on the possible combination of ibrutinib and CAR T-cell therapies

video-image

David Miklos, MD, PhD, explains how ibrutinib is being studied for the treatment of GVHD

video-image

David Miklos, MD, PhD, describes the optimal way to use ibrutinib in the treatment of GVHD

video-image

David Miklos, MD, PhD, on the outcomes of the ZUMA-1 clinical study

video-image

Michael Boxer, MD, on how obinutuzumab and bendamustine impacts quality of life in CLL patients

video-image

Michael Boxer, MD, considers broader uses for fostamatinib

video-image

Paul Richardson, MD, on the importance of real world evidence (RWE)

video-image

Paul Richardson, MD, shares the efficacy outcomes of GSK-916 in relapsed/refractory MM patients

video-image

Paul Richardson, MD, on adding CAR T-cell therapy to multiple myeloma treatment algorithms

video-image

Robert Soiffer, MD, on other applications that IL-2 might have outside of treating chronic GVHD

video-image

Robert Soiffer, MD, on some of the innovative approaches to treating chronic GVHD

video-image

Robert Soiffer, MD, discusses current treatments available for chronic GVHD

video-image

Robert Soiffer, MD, explains GVHD and some of the complications that come along with it

video-image

Jane N. Winter, MD, discusses how CAR T-Cell therapies will impact the treatment of lymphomas

video-image

Jane N. Winter, MD, shares the clinical evidence supporting brentuximab vedotin in older patients

video-image

Jane N. Winter, MD, on whether checkpoint inhibitors can be used effectively in Hodgkin’s Lymphoma

video-image

Jane N. Winter, MD, explains how PD-1 and PD-L1 expression changes the way DLBCL is treated

video-image

Robert M. Rifkin, MD, on excluding transplantation from MM treatment algorithms

video-image

Robert M. Rifkin, MD, discusses if COMPASS is close to its goal of achieving whole genome sequencing

video-image

Robert M. Rifkin, MD, on the Connect Multiple Myeloma patient registry improving characterization

video-image

Robert M. Rifkin, MD, on how the Connect Multiple Myeloma patient registry is helping patients

video-image

Andre Goy, MD, tells us about the long-term outcomes of the ZUMA-1 trial

video-image

Andre Goy, MD tells us about the BTK combination with lenalidomide in MCL

video-image

Andre Goy, MD, discusses the best strategy for using ibrutinib in MCL

video-image

David S. Siegel, MD, shares his thoughts on the most exciting clinical trial presented at ASH 2017

video-image

David S. Siegel, MD, discusses proteasome inhibitors and Multiple Myeloma

video-image

David S. Siegel, MD, discusses how stem cell transplant figures into MM treatment algorithms

video-image

David S. Siegel, MD, on how molecular profiling is helping drive treatment strategies

video-image

C. Ola Landgren, MD, discusses remaining major unmet medical needs for MM

video-image

C. Ola Landgren, MD, discusses risk factors for developing AML or MDS after treatment of MM

video-image

C. Ola Landgren, MD, discusses continuous therapy vs fixed duration therapy in MM patients

video-image

C. Ola Landgren, MD, on MRD as a legitimate surrogate endpoint in multiple myeloma clinical trials

video-image

John Gerecitano, MD, discusses the medical unmet needs in the treatment of follicular lymphoma

video-image

John Gerecitano, MD, on what genetic predictors of response we have for follicular lymphoma

video-image

John Gerecitano, MD, discusses how PET staging affects outcomes and prognosis of follicular lymphoma

video-image

John Gerecitano, MD, on predictors of response to tazemetostat in diffuse large B-cell lymphoma

video-image

John Gerecitano, MD, talks about tazemetostat’s class and mechanism of action

video-image

Miles Prince, MD, discusses I-O compounds and T-Cell Lymphoma treatment algorithms

video-image

Miles Prince, MD, on which emerging compounds for T-Cell Lymphomas look promising

video-image

Miles Prince, MD, on the challenges to recruit and accrue patients to rare-cancer clinical studies

video-image

Miles Prince, MD, discusses the efficacy and safety of brentuximab vedotin to treat CTCL patients

video-image

Miles Prince, MD, on the role CD30 plays when selecting a treatment algorithm for CTCL patients

video-image

Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients

video-image

Sattva Neelapu, MD, on novel agents and up-front approaches showing efficacy in lymphomas

video-image

Sattva Neelapu, MD, shares his approach to optimizing CAR T-Cell therapies

video-image

Sattva Neelapu, MD, discusses efficacy results of the ZUMA-1 trial

video-image

John P. Leonard, MD, on the role social media plays in medicine

video-image

John P. Leonard, MD, on CAR-T cell therapies being developed for the treatment of lymphomas

video-image

John P. Leonard, MD, on the role checkpoint inhibitors play in lymphoma treatment algorithms

video-image

John P. Leonard, MD, discusses novel agents for treating aggressive lymphomas

video-image

Gary Gordon, MD, PhD, on MRD endpoint for outcomes in the MURANO study

video-image

Gary Gordon, MD, PhD, discusses safety concerns in the phase 3 MURANO clinical trial

video-image

Gary Gordon, MD, PhD, discusses efficacy results of the phase 3 MURANO clinical trial

video-image

Matthew Davids, MD, on how checkpoint inhibitors are being developed for hematologic malignancies

video-image

Sagar Lonial MD, FACP, on expectations for response in the challenging patient type

video-image

Sagar Lonial MD, FACP, on MM patients not responding to monotherapy and combination regimens

video-image

Sagar Lonial MD, FACP, discusses unmet need for multiple myeloma patients

video-image

Sagar Lonial MD, FACP, on predicting venetoclax sensitivity in MM using biologic active assays

video-image

Bruce D. Cheson, MD, on the role of nivolumab in Hodgkin Lymphoma

video-image

Bruce D. Cheson, MD, discusses care, toxicities, and outcomes treating CLL patients with venetoclax

video-image

Bruce D. Cheson, MD on choosing a front-line therapeutic regimen for CLL patients

video-image

Sattva Neelapu, MD shares his advice for sites that are new to treating with CAR T-Cell therapies

video-image

Sattva Neelapu, MD shares safety results of the ZUMA-1 trial in patients with NHL

video-image

Matthew Davids, MD discusses his study using ibrutinib plus FCR in younger CLL patients

video-image

Matthew Davids, MD discusses how he typically treats front line CLL outside of a clinical study

video-image

John P. Leonard, MD discusses improving outcomes in high risk follicular lymphoma patients

video-image

Sagar Lonial MD, FACP tells us about the immunomodulatory mechanism of action of daratumumab

video-image

Sagar Lonial MD, FACP on whether relapsed multiple myeloma patients should be profiled molecularly

video-image

Bruce D. Cheson, MD discusses the efficacy and safety of acalabrutinib in relapsed/refractory MCL

video-image

John P. Leonard, MD discusses lenalidomide plus rituximab for the treatment of MCL

video-image

Jeff Sharman, MD, offers perspective on CAR T-cell therapies for the treatment of NHL

video-image

Kathryn Kolibaba, MD, lists key takeaways from the lymphoma oral session at ASCO 2017

video-image

Kathryn Kolibaba, MD, shares the results of the MAGNIFY study presented at ASCO

video-image

Kathryn Kolibaba, MD, describes the results of the BRIGHT study in front-line indolent NHL patients

video-image

Sattva Neelapu, MD, on new targets being evaluated which could make CAR-T therapies more effective

video-image

Sattva Neelapu, MD, on the possibility to enhance T-cell proliferation for a higher response rate

video-image

Sattva Neelapu, MD, on when we may see widespread availability of CAR-T therapies

video-image

Matthew Davids, MD, MMSc, on the potential benefits of utilizing checkpoint blockade

video-image

Matthew Davids, MD, MMSc, talks about his ASH 2016 presentations

video-image

Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML

video-image

Andrzej Jakubowiak, MD, PhD, discusses which new drugs are most compelling

video-image

Andrzej Jakubowiak, MD, PhD, relays big changes in the evolving role of immunomodulatory therapy

video-image

Michael Kauffman, MD, on Selinexor regulatory and commercialization plans

video-image

Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016

video-image

Edward Copelan, MD, on the most exciting presentations coming out of ASH 2016

video-image

David Miklos, MD, on developing an orphan drug for a small population of patients

video-image

Miles Prince, MD, on if any positive news for CTCL patients will be coming out of ASH 2016

video-image

Miles Prince, MD, on how CTCL patients will be impacted by treatment with brentuximab vedotin

video-image

Jane Winter, MD, on how immunotherapies are being incorporated into treatment for lymphoma patients

video-image

C. Ola Landgren, MD, PhD, on his optimism about the use of immunotherapies to treat MM patients

video-image

C. Ola Landgren, MD, PhD, provides insight into the treatment algorithm for smoldering MM patients

video-image

C. Ola Landgren, MD, PhD, on which multiple myeloma should be tested for MRD and why

video-image

C. Ola Landgren, MD, PhD, on how physicians should manage patients who test MRD negative

video-image

Swaminathan Iyer, MD, discusses exciting new CLL treatment options

video-image

Swaminathan Iyer, MD, relays the latest T cell lymphomas news coming out of ASH 2016

video-image

Swaminathan Iyer, MD, discusses intriguing data on CLL presented at ASH 2016

video-image

Alexander Perl, MD, on AML trial results presented at this year’s ASH meeting

video-image

Alexander Perl, MD, discusses treatment options for patients with FLT3-ITD positive AML

video-image

Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML

video-image

Alexander Perl, MD, discusses treatment options for AML patients

video-image

Chadi Nabhan, MD, on attention grabbing presentation in CLL at ASH 2016

video-image

Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors

video-image

Nikhil C. Munshi, MD, discusses his optimism about the use of immunotherapies to treat MM patients

video-image

Nikhil C. Munshi, MD, on whether we can start to associate the word “cure” with MM patients

video-image

Nikhil C. Munshi, MD, discusses the exciting news at ASH multiple myeloma patients

video-image

Nikhil C. Munshi, MD, on how physicians should sequence therapies in untreated MM patients

video-image

Lauren Pinter-Brown, MD, on improving quality of life for patients with T-cell lymphomas

video-image

Lauren Pinter-Brown, MD, explains refractory vs. relapsed peripheral T-cell lymphoma patients

video-image

Frederick Locke, MD, on the timing of when we could see widespread availability of CAR-T therapies

video-image

Frederick Locke, MD, on if CAR-T may replace transplantation when treating B-cell lymphomas

video-image

Frederick Locke, MD, explains the ZUMA-1 results and what it means to DLBCL patients

video-image

Parameswaran Hari, MD, talks about which stem cell transplantation studies are most exciting in MM

video-image

Parameswaran Hari, MD, on stem cell transplant and the treatment of high and low risk MM patients

video-image

Parameswaran Hari, MD, discusses stem cell transplantation and the treatment of myeloma

video-image

Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients

video-image

Aref Al-Kali, MD, reflects on the BEAT AML master trial and individualized therapy for AML patients

video-image

Aref Al-Kali, MD, explains how the CPX 351 data may impact how AML patients are treated if approved

video-image

Shaji Kumar, MD, shares his thoughts on whether multiple myeloma can be cured one day

video-image

Shaji Kumar, MD, discusses sequencing agents in the treatment of multiple myeloma

video-image

Shaji Kumar, MD, explains the impact personalized medicine will have on treatment of MM

video-image

Shaji Kumar, MD, explains how immunotherapies are being integrated into treatment algorithms for MM

video-image

Michael Kauffman, MD, on evidence that Selinexor is helping relapsed, refractory MM patients

video-image

Michael Kauffman, MD, on how Selinexor works

video-image

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

video-image

Chadi Nabhan, MD, weighs in on the treatment of elderly patients with hematological malignancies

video-image

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

video-image

Matthew Davids, MD, relays the most exciting clinical advances in CLL at ASH 2016

video-image

Andrzej Jakubowiak, MD, PhD, on the key takeaways from presentations at ASH 2016 on KRD

video-image

Matthew Davids, MD, talks about the advances in CLL and the unmet medical need for these patients

video-image

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

video-image

Andrzej Jakubowiak, MD, PhD, on the role of selinexor and the STORM trial and its future development

video-image

Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patients

video-image

Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patients

video-image

Edward Copelan, MD, on how he reduced the number of days for donors to provide cells for autologous BMT

video-image

Edward Copelan, MD, discusses the Levine Cancer Institute Program

video-image

David Miklos, MD, on the impact stem cell and bone marrow transplant have on patients

video-image

David Miklos, MD, discusses the outcomes in the phase 2 ibrutinib study for chronic GvHD

video-image

Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL

video-image

Jane Winter, MD, talks about how personalized medicine is being applied to NHL

video-image

Jane Winter, MD, relays the most exciting news at ASH 2016 for NHL patients

video-image

C. Ola Landgren, MD, PhD, opines on how to base treatment decisions on MRD test results

video-image

C. Ola Landgren, MD, PhD, relays his thoughts on the most exciting news at ASH for MM patients

video-image

Swaminathan Iyer, MD, on how romidepsin can be incorporated into the treatment of T cell lymphoma

video-image

Swaminathan Iyer, MD, discusses how to incorporate ofatumumab into the treatment of CLL

video-image

Alexander Perl, MD, on how the BEAT AML master trial will change the way AML patients are treated

video-image

Alexander Perl, MD, discusses how molecular testing can facilitate decision making in AML patients

video-image

Nikhil Munshi, MD, explains how the multiple myeloma genome project will personalize treatment of MM

video-image

Nikhil C. Munshi, MD, discusses the goals for the multiple myeloma genome project

video-image

Sattva Neelapu, MD, explains what the results of ZUMA-1 mean to DLBCL patients

video-image

Sattva Neelapu, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in T-cell lymphomas presented at ASH

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in cutaneous lymphomas presented at ASH

video-image

Frederick L. Locke, MD, discusses what new targets could make CAR-T therapies more effective

video-image

Frederick L. Locke, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Susan O’Brien, MD, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016

video-image

Susan O’Brien, MD, discusses CLL presentations at ASH 2016

video-image

Parameswaran Hari, MD, explains the effectiveness of novel immunotherapies in the treatment of multiple myeloma

video-image

Parameswaran Hari, MD, discusses the latest developments in stem cell transplantation at ASH 2016

video-image

Aref Al-Kali, MD, talks about the importance of the AGIOS 221 data

video-image

Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML

video-image

Shaji Kumar, MD, discusses venetoclax and why it stands out as one of the most promising compounds being presented at ASH 2016

video-image

Shaji Kumar, MD, discusses selinexor and why it stands out as one of the most promising compounds being presented at ASH 2016 (part 2)

video-image

Shaji Kumar, MD, discusses the most exciting treatment options for multiple myeloma today

video-image

Dana Farber IFM 2009 Phase III Study of the Intergroupe Francophone Du Myelome from ASH 2015

video-image

ASH 2015 Data Promises Immunotherapy Revolution in Multiple Myeloma with Pembrolizumab

video-image

Precision Medicine Coming to Bone Marrow Transplant

video-image

Venetoclax Produces Good Responses for 17p Deletion May Be Approved in 2016

video-image

Advances In B-Cell Lymphoma From ASH 2015

video-image

Real World Experience Idelalisib - Rituximab Combination for Relapsed CLL